DNAJA2 and melanoma: More strikingly, the data from a melanoma cohort treated with anti-CTLA4 antibody48,49 showed that patients with lower levels of DNAJA2 expression were greatly benefitted from the therapy than those with higher levels of DNAJA2 expression (Fig. 7h).